Krystal Biotech rises on new phase 1 data for cystic fibrosis asset

 

• Krystal Biotech (KRYS) is up ~5% in Friday afternoon trading after reporting additional positive phase 1 data for KB407 for cystic fibrosis.
• The CORAL-1 dose escalation study is examining KB407 at one, two, or four daily administrations via inhalation. The latest data is on the highest dose cohort. Prior data on the other cohorts was reported in December 2024.
• The percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% in the latest data.
• One serious adverse event of asthma exacerbation in this group was reported 24 hours after finishing bronchoscopy, but was later determined to be procedure related.

https://www.msn.com/en-us/health/other/krystal-biotech-rises-on-new-phase-1-data-for-cystic-fibrosis-asset/ar-AA1TUxWj